TY - JOUR
T1 - Assuring Quality for Non-Hospital-Based Biologic Infusions in Pediatric Inflammatory Bowel Disease
T2 - A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition
AU - Barfield, Elaine
AU - Sockolow, Robbyn
AU - Hoffenberg, Edward
AU - Saeed, Shehzad
AU - Kim, Sandra
AU - Siebold, Leah
AU - Picoraro, Joseph
AU - Moses, Jonathan
AU - Dykes, Dana
AU - Grossman, Andrew
AU - Wahbeh, Ghassan
AU - Park, K. T.
N1 - Publisher Copyright:
© 2018 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - The primary aim of this Clinical Report by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition is to provide formal guidance to pediatric gastroenterologists and clinicians, health systems, and insurance payers regarding home- and office-based infusions for biologic therapies in pediatric inflammatory bowel disease (IBD). Patients in North America are increasingly denied coverage by payers based on “place of service” codes at hospital-based infusion units where the treating clinicians primarily provide care. A task force with topic expertise generated 8 best practice recommendations to ensure quality of care for pediatric patients with IBD receiving non-hospital based biologic infusions. Pragmatic considerations discussed in this report include patient safety, pediatric-trained nurse availability, care coordination, patient-centeredness, shared liability, administrative support, clinical governance, and costs of care.
AB - The primary aim of this Clinical Report by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition is to provide formal guidance to pediatric gastroenterologists and clinicians, health systems, and insurance payers regarding home- and office-based infusions for biologic therapies in pediatric inflammatory bowel disease (IBD). Patients in North America are increasingly denied coverage by payers based on “place of service” codes at hospital-based infusion units where the treating clinicians primarily provide care. A task force with topic expertise generated 8 best practice recommendations to ensure quality of care for pediatric patients with IBD receiving non-hospital based biologic infusions. Pragmatic considerations discussed in this report include patient safety, pediatric-trained nurse availability, care coordination, patient-centeredness, shared liability, administrative support, clinical governance, and costs of care.
KW - biologics
KW - Crohn disease
KW - home infusions
KW - home-based infusions
KW - infliximab
KW - ulcerative colitis
KW - vedolizumab
UR - http://www.scopus.com/inward/record.url?scp=85044197020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044197020&partnerID=8YFLogxK
UR - https://corescholar.libraries.wright.edu/pediatrics/587
UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866197/
U2 - 10.1097/MPG.0000000000001890
DO - 10.1097/MPG.0000000000001890
M3 - Article
C2 - 29324477
SN - 0277-2116
VL - 66
SP - 680
EP - 686
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
IS - 4
ER -